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HLA plays a critical role in hematopoietic cell
ransplantation, but a full understanding of this role is
onstantly in ﬂux because of changing technologies
nd burgeoning amounts of clinical transplantation
esults. Today the clinician considering unrelated donor
ransplantation must also consider stem cell source: an
dult donor or an umbilical cord blood unit (CBU). In
he context of cord blood, the task is further compli-
ated by the strong interaction of cell dose.
Each individual carries from 10 to 12 genes that
ncode the HLA-A, HLA-B, HLA-C, HLA-DR, HLA-
Q, and HLA-DP molecules. Most of these genes are
ighly polymorphic, ranging from 13 (HLA-DRB4) to
99 (HLA-B) alleles at a locus [1]. Most of the allelic
ifferences result in changes in the HLA protein se-
uences, thus producing potential targets for allorecog-
ition [2]. The frequency of alleles differs in different
opulations: some are common in most populations,
nd others are found predominantly in only 1 or a few
opulations. The same is true for HLA haplotypes—the
ollection of multiple HLA alleles within a short re-
ion of chromosome 6—which are typically inherited
s a single block of genetic information. Table 1 pro-
ides examples.
DNA-based testing methods provide an accurate
nd powerful approach to identify HLA diversity, and
hese are replacing serologic testing [3,4]. DNA test-
ng detects speciﬁc nucleotide differences that distin-
uish alleles or sets of alleles. The ability to distin-
uish among particular alleles at a locus (ie, the
esolution) depends on the methodology, the set of
ligonucleotide reagents used in the assay, or both.
he choice of assay depends on the purpose of the
yping, eg, initial testing of newly recruited volunteers
r CBUs for a registry (low to intermediate resolu-
ion) compared with testing of transplantation candi-
ates and a few selected potential donors or CBUs
high or allele-level resolution). C
8LA IMPLICATIONS FOR SELECTING ADULT
NRELATED DONORS
Since 1987, the National Marrow Donor Program
NMDP) has facilitated hematopoietic cell transplan-
ations from unrelated donors. Until 1999, almost all
f these transplantations used donor bone marrow,
hereas today more than half use mobilized periph-
ral blood stem cells (PBSCs). Most recently, more than
5 000 CBUs have also been added to theNMDP donor
egistry, and another approximately 140 000 CBUs are
vailable worldwide [5].
In 1995, the NMDP initiated a project to identify
ll HLA alleles carried by transplant recipients and
heir donors and to associate the level of matching
ith outcome [6]. The data generated from this on-
oing study, combined with those from independent
nvestigations, have provided considerable insight into
he role of HLA in unrelated donor bone marrow
ransplantation. NMDP investigators authored a set
f recommendations for selection of unrelated adult
onors in 2004 [7]. The recommendations focused on
urvival, as opposed to other outcomes such as en-
raftment and graft-versus-host disease (GVHD), and
ncluded considerations from a large study in Japan
nd from studies of the Fred Hutchinson Cancer Re-
earch Center (FHCRC) group [8-12]. Although these
sets of studies differed in their designs and ﬁnal con-
lusions, they suggested that matching for HLA-C, in
ddition to HLA-A, -B, and -DRB1, is important for
verall survival (Table 2). In addition, the studies sug-
ested that matching at the allele (or high-resolution)
evel conferred additional beneﬁt over matching at an
ntigen level (ie, information available through sero-
ogic typing or low- or intermediate-level molecular
yping). The NMDP study further concluded that
ismatches between alleles (eg, 0401 versus 0404)
ere less detrimental than mismatches between anti-
ens (eg, 0401 versus 1301).
These results led the NMDP Histocompatibility
ommittee to recommend allele-level typing of the
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Advances in HLA
Botential recipient at HLA-A, -B, -C, and -DRB1 for
he purposes of searching and matching [7]. An ideal
onor would clearly be one whose alleles match the
ecipient at HLA-A, -B, -C, and -DRB1. The NMDP
ata failed to show any additional beneﬁt for matching
t HLA-DQ or HLA-DP, although HLA-DQ link-
ges are valuable in selecting partially typed donors
or more detailed evaluation. In the absence of an 8/8
llele–matched donor, the NMDP recommended mini-
izing the number of allele-level mismatches in total
ithout preferentially weighing any particular locus, eg,
LA-DRB1 as more important than HLA-A, -B, or -C.
f antigen mismatching is unavoidable, then the number
f additional allele-level mismatches should still be min-
mized. What remained unknown, however, was how
o balance allele mismatches against antigen mis-
atches (ie, what number of allele mismatches equals
n antigen mismatch).
It is important to note that the effect of a single-
llele mismatch (HLA-A, -B, -C, -DRB1, -DQB1, or
DPB1) may vary with the underlying diagnosis. In a
ecent publication on 948 donor-recipient pairs at the
HCRC, it was found that a single-allele mismatch
onferred a higher risk of death, but only for low-risk
atients, deﬁned as CML within 2 years of diagnosis
13]. In contrast, a single-allele mismatch had no ef-
ect on survival among higher-risk patients, ie, those
ith more advanced CML, acute leukemia, or myelo-
ysplastic syndrome.
Notably, in contrast to the NMDP study, the
HCRC study found that among the low-risk pa-
ients, a single-allele mismatch had the same negative
ffect as a single-antigen mismatch [13]. Furthermore,
heir results suggested that when multiple mismatches
able 1. Examples of Differences in Allele and Haplotype Frequencies
n Different Populations
Population Group Average Frequency
*4601 allele frequency [26]
Black 5 in 10 000 black individuals
White 4 in 10 000 white individuals
Asian 567 in 10 000 Asian individuals
Native American 0 in 10 000 Native Americans
aplotype frequency*
A*0101, B*0801, DRB1*0301 1 in 15 whites, 1 in 75 blacks
A*3001, B*4201, DRB1*0302 1 in 48 blacks, almost never in
whites
Unpublished data.
able 2. Effect of HLA Mismatching on Survival
Study A B
MDP [6] Decreased Decreased
HCRC [10] Merged A, B, and C d
MDP [8] Decreased DecreasedMDP indicates Japan Marrow Donor Program.
B&MTere unavoidable, HLA-DQ mismatches were more
etrimental. Although the effect of HLA-DQ in the
etting of multiple mismatches remains to be con-
rmed, these results clearly illustrate the complexity
f the HLA matching.
A few points are worth emphasizing with respect
o HLA and adult donor selection. First, essentially all
he available information pertains to bone marrow
ransplantation. It is unknown whether the results will
ertain to recipients of PBSC grafts. Because PBSCs
iffer from bone marrow in the numbers of CD34
ells and lymphocyte content, which may account for
ifferences in clinical “behavior” (eg, more rapid neu-
rophil engraftment and altered patterns of GVHD),
t is possible that lessons learned for marrow may not
pply to PBSCs. Second, the inﬂuence of reduced-
ntensity conditioning regimens on the principles of
LA matching is also largely unknown. Finally, the
otential role of killer inhibitory receptors and their
igands in relation to unrelated donor selection is
nknown. When the use of T cell–replete grafts
rom adult unrelated donors is considered, there
re no data to justify selection of donors who are
LA-C mismatched outside the context of a re-
earch study.
Another difﬁcult decision for physicians is whether
o wait for a better matched donor or CBU to be re-
ruited when no suitable donor or cord currently exists
or a patient. Whether waiting is a reasonable strategy
assuming, of course, that the patient’s condition is
table) depends on the patient’s HLA type. If a white
atient with slightly less common haplotypes has no
atched donor, there is a modest likelihood that 1 of
he 20 000 new donors recruited each month may be
he match. However, if the patient is of multiple race
eritages (eg, Asian and Caribbean black) or has rare
lleles, the probability of ever ﬁnding a perfectly
atched unrelated donor is negligible. Waiting for a
etter donor is always a matter of balancing the risks
nvolved, but understanding the patient’s haplotypes
nd having access to detailed allele and haplotype
requency tables by race could provide some direction
n a case-by-case basis. The enhancements to the
MDP matching algorithm described below will be
specially helpful in providing probability estimates
hat are useful for making these types of decisions.
ismatched HLA Locus
C DRB1 DQ
Decreased Decreased None
ed Merged DRB1 and DQ decreased
None Merged DRB1 and DQ noneM
ecreas29
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3LA IMPLICATIONS FOR SELECTING CBUS
Far less information is available to clarify the precise
ole of HLA in the setting of umbilical cord blood
UCB) transplantation. Overall, there have been fewer
CB transplantations (approximately 6000 worldwide),
ost have been children with acute leukemia and non-
alignant disease, data on HLA matching are less com-
lete in terms of the availability of high-resolution typ-
ng, and the effect of HLA is confounded by the
nteraction of nucleated cell dose. Most reports have
valuated the effect of mismatching at the intermediate-
esolution antigen level for HLA-A and -B and the allele
evel for -DRB1. HLA-C data and allele-level class I data
re rarely available. Nevertheless, Rubinstein et al. [14],
n their 1998 report on 562 CBU transplantations,
bserved that better matching at HLA-A and -B (an-
igen level) or -DRB1 (high resolution) predicted im-
roved survival. In this milestone study, recipients
ith 0 or 1 HLA mismatches had a lower risk of
onrelapse events (death, autologous recovery, or re-
ransplantation) than those with 2 mismatches.
Similarly, Wagner et al. [15] observed an indepen-
ent effect of HLA match and cell dose on 2-year
urvival in 102 UCB recipients who underwent trans-
lantation at a single institution. In contrast, Gluck-
an et al. [16], who analyzed Eurocord data on 550
CB recipients who underwent transplantation for
ematologic malignancies, reported that increasing
egrees of HLA disparity had no effect on transplant-
elated mortality or overall survival. Notably, in this
tudy, greater HLA disparity was associated with re-
uced neutrophil and platelet engraftment, an in-
reased risk of acute GVHD, and a lower risk of
elapse.
Two recent publications reported on adults who
nderwent UCB transplantation [17,18]. In both stud-
es, HLA matching was again reported at the serologic
evel for HLA-A and -B and at the allele level for HLA-
RB1. In the European Group for Blood and Marrow
ransplantation/Eurocord study, all 584 bone marrow
ecipients were HLA matched, and 92 (94%) of 98
CB recipients were mismatched [17]. Despite this
ifference, transplant-related mortality, relapse, and
verall survival were comparable between the 2
roups. In the US study, 450 adults received bone
arrow, and 150 received UCB (77% were mis-
atched at 2 HLA loci) [18]. In contrast to the Eu-
ocord study, survival after UCB transplantations was
nferior to that after marrow transplantation from an
LA-matched adult donor and was comparable to
hat after a 1 antigen/allele–mismatched adult donor.
aken together, both these studies suggest that with
espect to survival, UCB is less HLA restricted than
dult bone marrow.
Most recently, the Institute of Medicine commis-
ioned a study of UCB outcomes that pooled data t
0ontributed by the New York Blood Center, the
MDP, and the National Heart, Lung and Blood
nstitute Cord Blood Transplantation study [5]. A
otal of 755 cases representing transplantations of
hildren and adults in the United States were in-
luded. Matching for HLA-A and -B was evaluated at
he low to intermediate level, and HLA-DRB1 was
valuated at the allele level. The Institute of Medicine
tudy showed a clear effect of HLA matching on
urvival, with 6/6 matches faring better than 5/6 or
/6 matches. The magnitude of this effect, however,
as most apparent at lower cell doses (2.5  107
otal nucleated cells per kilogram). The Institute of
edicine report is the ﬁrst major study to emphasize
he effect of cell dose relative to HLA match with
ubstantial numbers of patients. The conclusion is that
LA mismatch cannot be evaluated without concom-
tant consideration of cell dose. The data suggest that
he greater the HLA disparity (0 versus 1 versus 2), the
reater the effect of cell dose on survival. A higher cell
ose can compensate, at least in part, for the negative
ffect of HLA disparity.
At this point, the precise role of HLA matching in
he setting of UCB transplantation is less clear than that
ith unrelated bone marrow transplantation. Although
ome studies have suggested that better matching at the
ntigen level improves survival or reduces transplant-
elated mortality, others have not made that association.
ell dose and differences in patient populations and
reatments confound these analyses. Still, the overall
ense is that when considering intermediate-level
LA-A and -B typing and allele-level HLA-DRB1, a
/6 or 6/6 match is preferred over a 4/6 match. Higher
ell doses (5  107 total nucleated cells per kilo-
ram), however, may overcome the negative effect of
LA mismatches [5].
Finally, few data are available to address the allele-
evel inﬂuences of HLA in UCB transplantation. The
S COBLT study recently reported on 32 young
hildren (4 years old) who received transplants for
reatment of various leukemias [19]. In this small co-
ort, allele-level HLA data revealed an association
etween matching and survival that was not evident in
he analysis of lower-resolution typing data.
MPROVING THE VALUE OF HLA DATA: STRATEGIES
OR INCREASING THE AVAILABLE INFORMATION
The HLA types of adult volunteers and CBUs are
isted within a registry database. Although increas-
ngly transplant centers use HLA allele-level matching
n their search for adult donors and CBUs, the speciﬁc
lleles carried by each potential donor/CBU appearing
n a search report usually are not known. For the pur-
oses of creating a searchable registry, donor/CBUHLA
ypes are almost always deﬁned at low to intermediate
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Advances in HLA
Besolution. This is because the HLA typing strategy
ust balance the resolution of HLA typing, which costs
ncreasingly more with increasing resolution, against the
esire to increase the total numbers of available donors
nd CBUs. New strategies, however, make it feasible to
lean additional information from even low- and inter-
ediate-resolution typing data. The techniques for se-
ecting donors and CBUs for testing with the greatest
ikelihood of a high-resolution match are outlined in
he remaining sections.
he Probability of Finding HLA-Identical Donors
n the Registry
Within the NMDP adult donor registry, the prob-
bility of identifying at least 1 antigen level–matched
HLA-A and -B) and potential allele level–matched
HLA-DRB1) matched donor varies within different
acial and ethnic populations. Probabilities for the
arious populations are as follows: white, 88%; black,
0%; Hispanics, 81%; Asian/Paciﬁc Islanders, 78%;
nd American Indians/Alaska Natives, 82% [20].
ithout consideration of cell dose, the probability of
nding at least 1 antigen-level HLA-A and -B and
otential allele -DRB1 CBU that is a 5/6, or better,
atch within the NMDP Cord Registry is 80% for
hites, 49% for blacks, 70% for Hispanics, 65% for
sian/Paciﬁc Islanders, and 80% for American Indians/
laska Natives. Once typed at a higher resolution,
ow many of these potential donors and CBUs will be
llele matches for the patient? The probability of
nding an allele match for speciﬁc patients varies
ramatically. Patients with common haplotypes will
nd many allele-matched donors. This is because a
onor or CBU that shares 6 antigens with 1 of these
atients has a very high likelihood that the antigen-
ncoding genes are arrayed along the same common
aplotypes possessed by the patient. The alternative
esult, namely, that the donor/CBU genes are arrayed
long less common haplotypes that just happen to give
he same 6 antigens, is statistically (and often dramat-
cally) less likely. So when 1 of these donors/CBUs is
yped at allele-level resolution, all of the alleles match,
ven those (eg, HLA-C) that were never previously
yped. In contrast, some patients have fairly common
LA alleles but uncommon haplotypes. In these
ases, it can be extremely difﬁcult to ﬁnd matched
onors. For other patients with rare alleles, matching
s very difﬁcult unless the allele is found in a conserved
aplotype (unpublished data).
The HLA diversity within a registry and the like-
ihood of matched donors can be evaluated with math-
matical algorithms [21,22]. These techniques make it
ossible to estimate the probability that certain low-
r intermediate-resolution HLA typings represent
peciﬁc known alleles. In other words, by generating
ables of allele-level, multiple-locus haplotype fre-
uency data, the logic can predict the HLA-A, -B, and e
B&MTDRB1 alleles without performing the high-resolution
yping.
he NMDP Search Algorithm in 2005
Within the NMDP registry, HLA assignments of
atients and donors (adults and CBUs) are converted
o a common nomenclature called search determinants
o allow comparison between the HLA types [23].
nce potential matches are identiﬁed, the algorithm
onverts the patient and donor search determinants
ack into their original nomenclature and prioritizes
atching relationships on the search report. Donors/
BUs with previously deﬁned HLA alleles identical to
he patient’s alleles appear ﬁrst on the search report,
ollowed by donors/CBUs with lower-resolution DNA
ssignment matches, followed by donors with serologic
yping (no CBUs are typed by serology methods) that
ndicates a potential match, followed by mismatched
onors and CBUs. On the basis of this search report, the
ransplant center, working with HLA experts, must pre-
ict which donors/CBUs might ultimately be allele
atched once typed at a higher resolution. If there are
any potential matches, only a few can be tested because
f constraints in time and patient resources. Choosing
he most likely matched pairs requires insight into the
eactivities of the HLA typing reagents used to per-
orm the initial typing and knowledge of HLA popu-
ation genetics. The NMDP is reﬁning its search al-
orithm to use this information.
LA DNA Data Behind the Scenes
To provide information on the reactivities of the
LA typing reagents for each adult donor, the
MDP has developed methods to collect HLA nu-
leotide polymorphisms detected as present or absent
n most new recruits [24]. This allows the registry to
onvert the HLA typing of a potential donor to a list of
lternative genotypes, thus conserving valuable informa-
ion about the allele pairs that can physically exist
n the donor. This is information that is normally lost in
he translation between the HLA typing laboratory and
he reporting of the result to the registry. The nucleotide
olymorphisms can be used later to determine whether a
onor might carry a newly described allele. This is often
ssential information required to facilitate searches for
atients who have many potential donors but for
hom the probability of those donors carrying the
atient’s alleles is very low.
ncorporating Population Genetics into
he Algorithm
One limitation in applying population genetics to
onor and CBU searching is the relatively small num-
er of individuals or CBUs typed for HLA at high
esolution. The problem is ampliﬁed within racial and
thnic subgroups, in which even fewer data are avail-
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3ble. To address this issue, biostatisticians and genet-
cists working with NMDP have developed a more
obust algorithm to predict allele-level haplotypes
unpublished data). The new algorithm will allow the
se of the varying-resolution HLA data in the 5.5
illion–donor NMDP registry to predict allele and
llele-level haplotype frequencies by race and ethnic-
ty. The registry has also used the high-resolution data
btained in its donor-recipient pair typing project to
dd to the haplotype data required for the improved
lgorithm [25]. The composite probability predictions
an be applied to all donors, including CBUs. For
very patient’s search, the potential for each donor or
BU to be an allele-level match with the patient can
e calculated. The integration of the nucleotide poly-
orphism data will ultimately increase the power to
redict whether a newly described allele could be
resent but was undetected in an older HLA typing.
ith this new logic, donors and CBUs will be sorted
n search reports according to their calculated overall
robability for allele matching with the patient at 6/6,
/6, or 4/6 (for CBU) for HLA-A, -B, and -DRB1.
Step Forward to Speed the Search for a
atched Donor
More than half (58%) of transplantations today
re for acutely ill patients for whom search time is
imited. Clearly, one of the profound advantages of
CB as a source of stem cells is its immediate avail-
bility. In some cases, a more mismatched UCB trans-
lantation (eg, 4/6) will be performed even if the cell
ose is borderline because of the length of time it
akes to identify and clear a volunteer adult donor
ven when he or she is HLA matched. To assist these
atients and expedite the search process, the NMDP
s building a more powerful search algorithm. The
ew reﬁnement will be especially helpful when physi-
ians are faced with long lists of potential adult or
BU donors but have resources and time to evaluate
nly a few from that list. The goal is to provide more
nformation on the search report to indicate the like-
ihood of each potential donor carrying the same al-
eles as the patient to streamline the donor/CBU se-
ection process and reduce the chance of overlooking
n optimal match.
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